Corticosteroids in inflammatory bowel disease: Are they still a therapeutic option?

Corticoides en la enfermedad inflamatoria intestinal: ¿siguen siendo una opción terapéutica?
Atención de salud Budesonida Budesonide Corticoesteroides Corticoides Corticosteroids Enfermedad inflamatoria intestinal Health care Inflammatory bowel disease Steroids Tratamiento Treatment

Journal

Gastroenterologia y hepatologia
ISSN: 0210-5705
Titre abrégé: Gastroenterol Hepatol
Pays: Spain
ID NLM: 8406671

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 09 07 2022
revised: 26 10 2022
accepted: 30 10 2022
medline: 27 10 2023
pubmed: 15 11 2022
entrez: 14 11 2022
Statut: ppublish

Résumé

Despite the development and incorporation of new therapeutic strategies, such as biologic therapy and small molecules, corticosteroids still play an important role in inducting inflammatory bowel diseases (IBD) remission. Variables like indicating the right doses at the right time, in adequate intervals, the security of these drugs and the pharmacological alternatives available must be considered by the providers when they are indicated to patients with IBD. Although the use of corticosteroids is considered as a marker of quality of care in patients with IBD, the use of these drugs in the clinical practice of IBD is far from being the correct one. This review article is not intended to be just a classic review of the indications for corticosteroids. Here we explain the scenarios in which, in our opinion, steroids would not be an appropriate option for our patients, as well as the most frequent mistakes we make in our daily practice when using them.

Identifiants

pubmed: 36375697
pii: S0210-5705(22)00263-1
doi: 10.1016/j.gastrohep.2022.10.017
pii:
doi:

Substances chimiques

Adrenal Cortex Hormones 0

Types de publication

Journal Article Review

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

716-726

Informations de copyright

Copyright © 2022 The Author(s). Publicado por Elsevier España, S.L.U. All rights reserved.

Auteurs

Rodrigo Quera (R)

Programa Enfermedad Inflamatoria Intestinal, Centro de Enfermedades Digestivas, Universidad de los Andes, Santiago, Chile.

Paulina Núñez (P)

Programa Enfermedad Inflamatoria Intestinal, Centro de Enfermedades Digestivas, Universidad de los Andes, Santiago, Chile; Sección de Gastroenterología, Departamento de Medicina Interna, Hospital San Juan de Dios, Facultad Medicina Occidente, Universidad de Chile, Santiago, Chile.

Beatriz Sicilia (B)

Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato Digestivo, Hospital Universitario de Burgos, Burgos, España.

Lilian Flores (L)

Programa Enfermedad Inflamatoria Intestinal, Centro de Enfermedades Digestivas, Universidad de los Andes, Santiago, Chile.

Fernando Gomollón (F)

Facultad de Medicina, Hospital Clínico Universitario, Instituto de Investigación Sanitaria de Aragón, CIBEREHD, Zaragoza, España. Electronic address: fgomollo@unizar.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH